Abstract
Biologic therapies have transformed the treatment landscape in oncology, offering targeted, immune-mediated, and personalized approaches to cancer management. Monoclonal antibodies, immune checkpoint inhibitors, and CAR-T cell therapies have shown remarkable clinical success in various malignancies. However, concerns regarding their safety, adverse effects, and long-term outcomes remain crucial. This article provides a comprehensive evaluation of the safety and efficacy of biologics in oncology, highlighting clinical trial data, post-market surveillance, and future directions in biologic drug development.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.